Boston Scientific Corporation (NYSE:BSX) SVP Maulik Nanavaty sold 57,031 shares of the company’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $27.28, for a total transaction of $1,555,805.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Maulik Nanavaty also recently made the following trade(s):

  • On Wednesday, August 30th, Maulik Nanavaty sold 27,031 shares of Boston Scientific Corporation stock. The stock was sold at an average price of $27.08, for a total transaction of $731,999.48.

Shares of Boston Scientific Corporation (NYSE BSX) opened at 27.50 on Friday. The firm has a market capitalization of $37.73 billion, a price-to-earnings ratio of 49.19 and a beta of 1.09. The company’s 50-day moving average is $27.02 and its 200 day moving average is $26.29. Boston Scientific Corporation has a 1-year low of $19.67 and a 1-year high of $28.51.

Boston Scientific Corporation (NYSE:BSX) last issued its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 EPS for the quarter, topping the consensus estimate of $0.31 by $0.01. Boston Scientific Corporation had a net margin of 9.04% and a return on equity of 23.62%. The company had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.21 billion. During the same quarter in the previous year, the company earned $0.27 EPS. Boston Scientific Corporation’s revenue was up 6.2% on a year-over-year basis. On average, analysts expect that Boston Scientific Corporation will post $1.26 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/09/03/maulik-nanavaty-sells-57031-shares-of-boston-scientific-corporation-bsx-stock.html.

Several large investors have recently modified their holdings of the company. Lord Abbett & CO. LLC acquired a new stake in shares of Boston Scientific Corporation during the second quarter valued at approximately $40,460,000. Sentry Investment Management LLC boosted its stake in shares of Boston Scientific Corporation by 1.1% in the second quarter. Sentry Investment Management LLC now owns 107,243 shares of the medical equipment provider’s stock valued at $2,973,000 after buying an additional 1,125 shares in the last quarter. WFG Advisors LP boosted its stake in shares of Boston Scientific Corporation by 17.3% in the second quarter. WFG Advisors LP now owns 157,919 shares of the medical equipment provider’s stock valued at $4,378,000 after buying an additional 23,305 shares in the last quarter. Toronto Dominion Bank boosted its stake in shares of Boston Scientific Corporation by 26.1% in the second quarter. Toronto Dominion Bank now owns 463,826 shares of the medical equipment provider’s stock valued at $12,854,000 after buying an additional 95,902 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd boosted its stake in shares of Boston Scientific Corporation by 80.8% in the second quarter. Dynamic Technology Lab Private Ltd now owns 16,800 shares of the medical equipment provider’s stock valued at $466,000 after buying an additional 7,507 shares in the last quarter. Institutional investors own 90.52% of the company’s stock.

Several research analysts have commented on the stock. BidaskClub cut shares of Boston Scientific Corporation from a “hold” rating to a “sell” rating in a research report on Saturday, August 26th. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Boston Scientific Corporation in a research report on Wednesday, August 9th. J P Morgan Chase & Co reiterated an “overweight” rating and issued a $31.00 price objective (up from $27.00) on shares of Boston Scientific Corporation in a report on Wednesday, June 28th. Cowen and Company reiterated a “buy” rating and issued a $32.00 price objective (up from $31.00) on shares of Boston Scientific Corporation in a report on Friday, July 28th. Finally, Zacks Investment Research upgraded shares of Boston Scientific Corporation from a “sell” rating to a “hold” rating in a report on Monday, July 31st. One analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Boston Scientific Corporation presently has an average rating of “Buy” and an average price target of $29.88.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Insider Buying and Selling by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Stock Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related stocks with our FREE daily email newsletter.